Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018

  • ID: 4592404
  • Drug Pipelines
  • 165 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • CytaCoat AB
  • Lakewood-Amedex Inc
  • Melinta Therapeutics Inc
  • Nabriva Therapeutics plc
  • Shionogi & Co Ltd
  • MORE
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

This latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 6, 8, 11, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • CytaCoat AB
  • Lakewood-Amedex Inc
  • Melinta Therapeutics Inc
  • Nabriva Therapeutics plc
  • Shionogi & Co Ltd
  • MORE
Introduction

Report Coverage

Hospital Acquired Pneumonia (HAP) - Overview

Hospital Acquired Pneumonia (HAP) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Cardeas Pharma Corp

Centauri Therapeutics Ltd

CytaCoat AB

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Evaxion Biotech ApS

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics plc

Polyphor AG

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Hospital Acquired Pneumonia (HAP) - Drug Profiles

(amikacin + fosfomycin) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(avibactam + aztreonam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

((avibactam + ceftazidime) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cefepime + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cefepime + zidebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ceftolozane sulfate + tazobactam sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(cilastatin sodium + imipenem + relebactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(meropenem + vaborbactam) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aerucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alalevonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbekacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol sulfate tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EBX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eravacycline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EVXB-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iclaprim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lefamulin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levonadifloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

murepavadin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NU-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Panaecin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

panobacumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-7001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polysaccharides for Hospital Acquired Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qn-2251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections and Ventilator Associated Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvratoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tedizolid phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telavancin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tosatoxumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZTI-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hospital Acquired Pneumonia (HAP) - Dormant Projects

Hospital Acquired Pneumonia (HAP) - Discontinued Products

Hospital Acquired Pneumonia (HAP) - Product Development Milestones

Featured News & Press Releases

Jun 06, 2018: Shionogi Announces Upcoming Presentations on Cefiderocol at American Society for Microbiology Microbe Meeting

May 09, 2018: Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development

Feb 01, 2018: FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Feb 01, 2018: FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jan 15, 2018: Pfizer’s Zavicefta Rejects For Use Within NHS Scotland

Jan 15, 2018: Pfizer’s Zavicefta Rejects for Use within NHS Scotland

Oct 04, 2017: Allergan To Present New Data on AVYCAZ At IDWeek 2017 In San Diego

Oct 04, 2017: Allergan To Present New Data on AVYCAZ At IDWeek 2017 In San Diego

Apr 24, 2017: Pivotal Phase III Study Underscores Efficacy Of Zavicefta (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals

Apr 19, 2017: Merck to Present Data on ZERBAXA at ECCMID 2

Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates

Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek 2

Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics plc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2018

Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2018

Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aridis Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cardeas Pharma Corp
  • Centauri Therapeutics Ltd
  • CytaCoat AB
  • Destiny Pharma Ltd
  • Dong-A Socio Holdings Co Ltd
  • Evaxion Biotech ApS
  • Lakewood-Amedex Inc
  • MedImmune LLC
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Motif Bio Plc
  • Nabriva Therapeutics plc
  • Polyphor AG
  • Sealife PHARMA GMBH
  • Shionogi & Co Ltd
  • Tetraphase Pharmaceuticals Inc
  • Theravance Biopharma Inc
  • Wockhardt Ltd
  • Zavante Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll